STAT3 pathway in cancers: Past, present, and future

82Citations
Citations of this article
101Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family, discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in biological functions. The duration of STAT3 activation in normal tissues is a transient event and is strictly regulated. However, in cancer tissues, STAT3 is activated in an aberrant manner and is induced by certain cytokines. The continuous activation of STAT3 regulates the expression of downstream proteins associated with the formation, progression, and metastasis of cancers. Thus, elucidating the mechanisms of STAT3 regulation and designing inhibitors targeting the STAT3 pathway are considered promising strategies for cancer treatment. This review aims to introduce the history, research advances, and prospects concerning the STAT3 pathway in cancer. We review the mechanisms of STAT3 pathway regulation and the consequent cancer hallmarks associated with tumor biology that are induced by the STAT3 pathway. Moreover, we summarize the emerging development of inhibitors that target the STAT3 pathway and novel drug delivery systems for delivering these inhibitors. The barriers against targeting the STAT3 pathway, the focus of future research on promising targets in the STAT3 pathway, and our perspective on the overall utility of STAT3 pathway inhibitors in cancer treatment are also discussed.

References Powered by Scopus

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

75872Citations
N/AReaders
Get full text

STATs in cancer inflammation and immunity: A leading role for STAT3

3581Citations
N/AReaders
Get full text

Stat3 as an oncogene

2615Citations
N/AReaders
Get full text

Cited by Powered by Scopus

From structural design to delivery: mRNA therapeutics for cancer immunotherapy

38Citations
N/AReaders
Get full text

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression

25Citations
N/AReaders
Get full text

Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition

20Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wang, H. Q., Man, Q. W., Huo, F. Y., Gao, X., Lin, H., Li, S. R., … Bu, L. L. (2022, June 1). STAT3 pathway in cancers: Past, present, and future. MedComm. John Wiley and Sons Inc. https://doi.org/10.1002/mco2.124

Readers over time

‘22‘23‘24015304560

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 23

70%

Researcher 6

18%

Professor / Associate Prof. 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 20

53%

Medicine and Dentistry 9

24%

Agricultural and Biological Sciences 5

13%

Pharmacology, Toxicology and Pharmaceut... 4

11%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0